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A Defect in the Ionotropic Glutamate Receptor 6 Gene (GRIK2)
Is Associated with Autosomal Recessive Mental Retardation
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Nonsyndromic mental retardation is one of the most important unresolved problems in genetic health care. Autosomal
forms are far more common than X-linked forms, but, in contrast to the latter, they are still largely unexplored. Here,
we report a complex mutation in the ionotropic glutamate receptor 6 gene (GRIK2, also called “GLUR6”) that cosegregates
with moderate-to-severe nonsyndromic autosomal recessive mental retardation in a large, consanguineous Iranian family.
The predicted gene product lacks the first ligand-binding domain, the adjacent transmembrane domain, and the putative
pore loop, suggesting a complete loss of function of the GLUK6 protein, which is supported by electrophysiological data.
This finding provides the first proof that GLUK6 is indispensable for higher brain functions in humans, and future studies
of this and other ionotropic kainate receptors will shed more light on the pathophysiology of mental retardation.
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To date, only three genes have been found to be directly
linked to nonsyndromic autosomal recessive mental re-
tardation (NS-ARMR): PRSS12 (also called “neurotrypsin”
[MIM 606709]), which encodes a trypsin-like serine pro-
tease1; CRBN (also called “cereblon” [MIM 609262]),2
which encodes an ATP-dependent Lon protease; and
CC2D1A (MIM 610055), which encodes a putative signal
transducer that participates in the positive regulation of
the I-kB kinase/NF-kB cascade.3 We recently reported eight
genomic loci for NS-ARMR (MRT4–MRT11)4 as the result
of linkage studies of 78 consanguineous Iranian families.
Here, we describe the first of the underlying gene defects,
resolving the MRT6 locus [MIM 611092], a 9.98-Mb in-
terval on chromosome 6q16.1-q21 that we found in a
family with moderate-to-severe NS-ARMR. The degree of
mental retardation (MR) in the affected family members
ranged from mild to severe (fig. 1). Patient V:1 had an
intelligence quotient (IQ) of 30 at age 50 years. His youn-
gest sister (V:5) had mild MR. Patients V:6 and V:12 also
had mild MR, and patient V:11 had an IQ of 55 (moderate
MR). The patients did not have neurological problems,
congenital malformations, or facial dysmorphisms. Body
height, weight, and head circumference were normal in
all patients. For patient V:12, we performed a magnetic
resonance imaging scan, which revealed no morpholog-
ical abnormalities. Sample collection and clinical evalu-
ation procedures were performed with the informed con-
sent of the parents and have been described elsewhere.4
The MRT6 locus contains 25 annotated genes; 8 of these
(GRIK2 [MIM 138244], CCNC, COQ3, MCHR2, GPR63,
KLHL32, POU3F2, and SIM1) were considered to be plau-
sible candidate genes for MR and were selected for mu-
tation screening. We designed PCR primers for the am-
plification of exonic sequences and splice-site regions,
using the Primer3 software.5 PCR amplicons (primer se-
quences and reaction conditions are available on request)
were analyzed by agarose-gel electrophoresis and direct
sequencing. In DNA from patients, only a single nonpo-
lymorphic sequence change was detected, apparently a
deletion removing exons 7 and 8 of the GRIK2 gene (see
fig. 2a for physical coordinates and exon-intron structure),
as suggested by our failure to amplify these exons by PCR.
GRIK2 encodes GLUK6, a subunit of kainate receptors
(KARs) that is highly expressed in the brain. Together with
the intensively studied alpha-amino-3-hydroxy-5-methyl-
4-isoxazole proprionic acid (AMPA) and N-methyl-D-
aspartic acid (NMDA) receptors, KARs belong to the ion-
otropic receptors that are the targets of glutamate released
in excitatory synapses.6,7 Mutation or loss of NMDA and/
or AMPA receptors is known to result in severe derange-
ment of neuronal function. Still, extensive analyses of
their structure, biophysical properties, and distribution8–10
have so far failed to define a role for ionotropic KARs in
higher brain functions. GRIK2 has been associated with
autism,11 but this finding could not be substantiated by a
recent genomewide linkage study,12 and behavioral studies
of Grik2-knockout mice did not yield conclusive results.10
Thus, the involvement of this receptor in cognition has
so far remained controversial.
Loss of exons 7 and 8 in GRIK2, as observed in our
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Figure 1. Family pedigree. Blackened symbols represent patients
with severe MR, three-quarters-blackened symbols represent pa-
tients with moderate MR, and half-blackened symbols represent
patients with mild MR.
Figure 2. Genomic mutation in GRIK2. a, Schematic representation of the GRIK2 wild-type allele. Physical coordinates (top) are
according to NCBI build 36.1. Exons are depicted by numbered arrowheads. Black shading indicates unaffected sequence, gray shading
indicates deleted regions, and the inversion is white outlined in black. A checkered pattern marks the uninverted sequence fragment
5′ of the deletion of exons 7 and 8. Squares, circles, and diamonds mark the positions of the deletion and inversion borders. Rectangular
symbols below the schematic of GRIK2 mark the locations of regions of low sequence complexity or repetitive elements. b, Schematic
representation of the GRIK2 mutant allele and the sequences of the 5′ and 3′ genomic junction fragments. LINE p long interspersed
nuclear element; SINE p short interspersed nuclear element.
patients with MR, results in an in-frame deletion of 84 aa
between amino acids 317 and 402, close to the first ligand-
binding domain (S1) in the extracellular N-terminal region
of GLUK6. To study whether this defect was sufficient to
impair GLUK6 protein function, we cloned wild-type
GLUK6 from human fetal brain RNA (BD Biosciences Clon-
tech), using the pENTR Directional Topo Cloning kit (In-
vitrogen) in accordance with the manufacturer’s instruc-
tions. We employed the resulting plasmid for subcloning
GRIK2 wild-type cDNA into modified (green fluorescent
protein [GFP] replaced with c-Myc tag) pcDNA-DEST47
Gateway vectors (Invitrogen). We then engineered a
GLUK6D construct lacking exons 7 and 8 by site-directed
mutagenesis with the QuikChange Site-Directed Mutagen-
esis Kit (Stratagene). For a cellular model system, we chose
HEK293 cells, because they do not show endogenous
GRIK2 expression, and cotransfected them with either
plasmid in combination with a green fluorescent trans-
fection marker (1.8 mg cDNA encoding either wild-type
GRIK2 or GRIK2D plus 0.2 mg pEGFP-N1 vector [BD Bio-
sciences Clontech]). The transfection reagent we used was
DreamFect (OZ Biosciences) or Fugene reagent (Roche).
For whole-cell patch-clamp recordings, cells were de-
tached with 1 mM EDTA in cold PBS, 24 or 48 h after
transfection, were transferred to poly-D-lysin–coated cov-
erslips, and were allowed to settle for at least 4 h. We
performed the recordings by using an intracellular solu-
tion containing 130 mM CsCl, 9.4 mM NaCl, 1 mM MgCl2,
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Figure 3. Loss of function of GLUK6D. a, Mean currents evoked by 100 mM kainate (for GLUK6 wild type [WT], ; for GLUK6D,np 8
). b, Dose-response curve for kainate, normalized to response in 100 mM kainate. Error bars represent SEM (for GLUK6WT,np 9 np
per reading point; for GLUK6D, per reading point). c, Cells expressing GLUK6WT show photolytically evoked glutamate6–8 np 3–9
responses without prior incubation in concanavalin A (black line), whereas GLUK6D-expressing cells show no currents after fast glutamate
application (gray line). Each trace represents the mean of five successive sweeps. d, Immunocytochemistry showing colocalization of
both GLUK6 WT and GLUK6D with the endogenous plasma membrane protein cadherin. DAPI p 4
′,6-diamidino-2-phenylindole.
0.2 mM guanosine triphosphate, 10 mM ethylene glycol
tetraacetic acid, and 10 mM HEPES (pH adjusted to 7.3
with CsOH). The cells were superfused with HEPES-buf-
fered solution (140 mM NaCl, 2.4 mM KCl, 10 mM glu-
cose, 10 mM HEPES, 2.5 mM CaCl2, and 1.3 mM MgCl2
[pH adjusted to 7.3 with NaOH]). We treated the cells for
5 min with 200 mg/ml concanavalin A in glucose-free ex-
tracellular solution immediately before the recordings, to
prevent lectin aggregation. Cells were voltage clamped at
60 mV, by use of an Axoclamp 700A. Recordings were
digitized with 5 kHz and were analyzed online by use of
IGOR Pro (Wavemetrics). All recordings were performed
at room temperature. Our results show that GLUK6D com-
pletely lost the ability to conduct ions when activated by
kainate (fig. 3a) or glutamate (data not shown), indepen-
dent of agonist dosage (fig. 3b). To exclude the possibil-
ity of altered receptor desensitization, we made use of a
fast application system13 for performing whole-cell patch-
clamp experiments without concanavalin A. For this flash
photolysis of glutamate, 40 mM 4-methoxy-7-nitroindol-
inyl–caged glutamate (Tocris) was perfused continuously
on the cells in a volume of 10 ml. A 355-nm UV laser
beam (DPSL-355-1W laser [Rapp Optics]) was coupled via
a 200-mm quartz fiber optic into a spot illumination adap-
tor (Rapp Optics), mounted in the epifluorescence path
of an Olympus BX51Wl microscope (equipped with a laser
beam splitter and a 420-nm-long pass emitter [both from
AHF Analysetechnik]) and was focused with a 60# water
objective (numerical aperture 0.9 [Olympus]) onto a spot
∼40 mm in diameter. The holding current was constant
during washing of the caged glutamate. Again, we ob-
served a complete loss of function of GLUK6D compared
with the wild-type GLUK6 channels (fig. 3c). We then asked
whether this might be caused by the absence of the re-
ceptor in the plasma membrane caused by a defect in re-
ceptor trafficking. Therefore, we performed GLUK6 staining
experiments in transfected HEK293 cells, fixed 48 h after
transfection with paraformaldehyde (4%, for 10 min at
room temperature) and permeabilized with Triton X-100
in PBS (0.1%, for 5 min at room temperature). The cells
were subsequently blocked with normal goat serum
(10%, for 1 h at room temperature). For detection of the
membrane protein cadherin and GLUK6, we used the an-
tibodies panCadherin (ab6528 [Abcam]) (1:2,000, for 1 h
at room temperature) and Anti-GLUR6/7 (05–921 [Upstate
Biotechnology]) (1:2,000, for 1 h at room temperature),
respectively. They were labeled by the secondary antibod-
ies Alexa Fluor 488 chicken anti-mouse (Invitrogen) (1:
1,000, for 1 h at room temperature) and Alexa Fluor 488
chicken anti-rabbit (Invitrogen) (1:1,000, for 1 h at room
temperature). Confocal analysis of GLUK6 stainings on a
laser-scanning microscope (Zeiss Axiovert 100 M) with a
63# objective, however, clearly showed colocalization of
transfected GLUK6D with the endogenous membrane pro-
tein cadherin in HEK293 cells (fig. 3d). Biotinylation ex-
periments confirmed that these cells had considerable
amounts of GLUK6 protein in the plasma membrane (fig.
4).
In parallel, we performed PCR experiments with various
primer combinations to define the borders of the deletion
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Figure 4. GLUK6D present on the plasma membrane of transfected
HEK293 cells. a, Membrane proteins biotinylated on HEK293 cells
overexpressing GLUK6 wild type (WT) or GLUK6D (Delta) at 48 h
after transfection (Pinpoint [Pierce]). Nontransfected HEK293 cells
served as a control (Mock). After cell lysis (Total Lysate samples),
biotinylated membrane proteins were bound to a NeutrAvidin af-
finity column. Nonbiotinylated protein was separated, because it
does not bind to the NeutrAvidin affinity column (Flow Through
samples). Membrane proteins were eluted with sample buffer (Elu-
ate samples). All fractions were separated on a 10% SDS gel, were
blotted, and were probed for GLUK6 (with 05-921 [Upstate Bio-
technology] at 1:800). GLUK6 WT and GLUK6D are present in the
membrane protein fraction (Eluate samples). b, Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) loading control (ab9482
[Abcam]).
Figure 5. Southern blots for patients and heterozygous carriers of the mutation, characterizing the 5′ border (a) (by use of BglII)
and the 3′ border (b) (by use of EcoRV) of the mutation.
but failed to amplify a junction fragment. We therefore
investigated the 5′ region of the putative deletion in all
available family members by Southern-blot analysis. Fol-
lowing standard procedures, we used 10 mg genomic DNA
for restriction with BglII and a 32P-labeled probe, directed
against a 802-bp sequence upstream of the mutation re-
gion (forward primer: 5′-gccattgtgtaagatcatagtgctcagac-3′;
reverse primer: 5′-gtatattagaaccactgggaagg-3′). The ex-
pected fragment size, corresponding to a GRIK2 allele lack-
ing exons 7 and 8, was 1.5 kb, yet we identified a 6.5-kb
band in carriers of the mutant allele (fig. 5a), which
pointed to the presence of a more complex genomic re-
arrangement. We then performed inverse PCR14 on 1 mg
of this fragment, isolated with the Qiaquick gel-extraction
kit (Qiagen). The fragment was circularized by self-ligation
in a 10-ml reaction volume by use of 1.5 U T4 DNA ligase
and the reaction buffer provided by the manufacturer. Af-
ter 16 h of incubation at 12C, the enzyme was inactivated
by increasing the reaction temperature to 65C for 10 min.
For PCR amplification, we used reverse-oriented primers
(forward primer: 5′-catgctcctagaggtgtgcaaatacc-3′; reverse
primer: 5′-ctacaatggcaagcgaagtg-3′) located 5′ of the mu-
tation in a region that could be amplified from patient
DNA. Cloning and sequencing of the amplicon confirmed
the deletion of exons 7 and 8 by uncovering a sequence
junction between the remnants of introns 6 and 8. This
junction fragment was joined to a sequence fragment be-
longing to intron 11 in reverse orientation. Through fur-
ther PCR and sequencing analyses and Southern-blot ex-
periments (fig. 5b), with use of EcoRV for DNA digestion
and a 930-bp upstream probe (forward primer: 5′-tggaaatt-
catagtaaaggtatgtgg-3′; reverse primer: 5′-ctgagtagaaagagag-
agaaacaatg-3′), we were able to elucidate the full extent
of the observed mutation. This is illustrated in figure 2,
which shows that, in addition to the ∼120-kb deletion
(spanning exons 7 and 8), the mutation comprises an in-
version of ∼80 kb, including exons 9, 10, and 11 in com-
bination with a deletion of ∼20 kb of intron 11. At the
protein level, this rearrangement can be expected to result
in the loss not only of the first ligand-binding domain but
also of the adjacent transmembrane domain and the pu-
tative pore loop of GLUK6 (fig. 6).
Cosegregation of the mutation with MR in the family
was shown by array-based comparative genomic hybrid-
ization (array CGH) and Southern-blot experiments (figs.
5 and 7). We also performed Southern blots on a panel of
172 individuals with university education. Neither these
nor any of 390 individuals from a random population
sample (healthy blood donors) screened by PCR carried
the mutation.
To check for GRIK2 expression, we extracted total RNA
from Epstein-Barr virus–transformed lymphoblastoid cell
lines of all available patients and healthy siblings by use
of the TRIzol reagent (Invitrogen). We isolated mRNA
(Dynabeads Oligo (dT)25 [Dynal Biotech]) and generated
cDNA by using the SuperScript III Reverse Transcriptase
(Invitrogen) together with random hexamers. This cDNA
was used to perform PCRs, by use of different combina-
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Figure 6. Impact of GRIK2 mutation on GLUK6 protein structure. Shown is a schematic representation of the GRIK2 wild-type allele
and a cartoon of a GLUK6 monomer. MI–MIIIp transmembrane domains; P p pore loop. Letters indicate the start and end of different
alterations in the genomic sequence and their corresponding impact on the resulting protein. a p deletion of exons 7 and 8; b p
complete genomic rearrangement, as observed in patients with MR; c p region lacking in the putative transcript with a junction
between exons 6 and 14.
tions of primers from exon 6 with primers from exons 12,
13, and 14. With a combination of primers from exon 6
(5′-gaaaagtggtcgatggaacg-3′) and exon 14 (5′-ggcccacattttg-
tcatacg-3′), we obtained an aberrant fragment in the cDNA
from homozygous and heterozygous carriers of the mu-
tation (data not shown). Compared with the transcript
expected from the deletion-inversion, this corresponds to
a transcript that translates into a GLUK6 protein, which
lacks an additional transmembrane domain (fig. 6). In
view of our finding that the deletion of exons 7 and 8 is
already sufficient to cause a complete loss of GLUK6 func-
tion, we conclude that the patients do not express any
GRIK2 gene product with the capacity to form functional
ion channels.
GLUK6-containing receptors are present at the presyn-
aptic level,18,19 as well as at the postsynaptic level,20 and
the primary involvement of GLUK6 in excitatory synaptic
activity suggests that defective GLUK6 might cause cog-
nitive impairment through alterations in local brain cir-
cuitry. An attractive hypothesis, in this respect, is that
KARs might be involved in the maturation of microcircuits
and network formation in brain areas that are important
for higher brain functions, such as the hippocampus. In
fact, it has been shown that, in mice, the expression level
of KAR-subunit mRNAs in the hippocampus is very high
during early stages of development, whereas adult animals
show lower levels.21,22 Furthermore, it has been found that,
in the rodent neonatal hippocampus, KARs are activated
by ambient glutamate and thereby regulate spontaneous
network activity and functional maturation of hippocam-
pal synapses.23,24
At the cellular level, it is conceivable that defective
GLUK6 could also have structural effects. Indeed, GLUK6
has been found to be involved in profilin II–mediated in-
teractions with actin,25,26 through which it might contrib-
ute to the stabilization of dendritic spine morphology27
and normal neuritogenesis.28 Further studies of this aspect
of GLUK6 function in model organisms will be particularly
interesting, because abnormal morphogenesis of dendritic
spines is observed in a variety of MR disorders, such as
fragile X syndrome (MIM 300624) (for review, see, e.g.,
the work of Grossmann et al.29). A third avenue to be
explored might be the investigation of a putative impact
of GLUK6 deficiency on synaptic plasticity. In this context,
it is noteworthy that GLUK6 also seems to interact with
synapse-associated protein 102,30 for which mutations in
the coding gene (DLG3) were found in families with severe
X-linked MR.31
By identifying GRIK2 as a likely NS-ARMR gene, we pro-
vide strong evidence that functional integrity of this ion-
otropic glutamate receptor might be a sine qua non for
normal human brain function. Given the unclear phe-
notype of Grik2-deficient mice, this study also indicates
that genotype-phenotype studies in man are indispens-
able for identifying the genes that play a role in complex
behavioral traits. Finally, we expect that our results will
stimulate research into the role of other KARs in cognition
and behavior. GRIK2 is the first gene for NS-ARMR with a
known function in the CNS. Its identification is part of
an ongoing systematic effort to unravel the molecular
causes of recessive MR, which will shed more light on the
function of the human brain in health and disease.
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Figure 7. Array CGH results for patients with MR. Submegabase-resolution array CGH was performed as described elsewhere.15 After
normalization by subgrid LOWESS, Cy3:Cy5 intensity ratios of each clone were plotted in a size-dependent manner along the chromosome
ideograms, by use of CGHPRO.16 Red and green bars indicate the log2 ratio thresholds of 0.3 (loss) and 0.3 (gain), respectively. A
homozygous deletion of 6q16.3 was the only aberration that cosegregated with the disease; it was present in all affected probands
and was absent in all unaffected probands tested. Array CGH data shown here have been deposited in NCBI Gene Expression Omnibus
(GEO)17 and are accessible through GEO series accession number GSE 7886. a, Close-up of findings for patient 6q16.3, demonstrating
a deletion of two BAC clones (RP11-226C08 and RP11-543M18 [arrows]) encompassing GRIK2. (Because of lower hybridization quality
for V:6, only one BAC represents the DNA copy-number loss.) b, Overall view of chromosome 6 in the corresponding patients. A red
rectangle highlights the region depicted in panel a.
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